ASCO 2024 | Novel therapies for head and neck cancers: bispecific antibodies and fusion proteins

Ari Rosenberg, MD, University of Chicago, Chicago, IL, discusses the exciting developments in novel therapies for recurrent metastatic head and neck cancers. He highlights promising therapies in development, including bispecific antibodies and multi-targeted fusion proteins, which target multiple pathways and co-localize effects within the tumor microenvironment. Notable assets include petosemtamab a bispecific antibody targeting EGFR and LGR5, showing single-agent activity in refractory patients. Additionally, frontline data of petosemtamab with pembrolizumab in PD-L1 enriched populations are anticipated. Dr Rosenberg also mentions BCA101, targeting EGFR and TGF-beta, demonstrating efficacy with pembrolizumab, especially in HPV-negative patients. Despite a negative outcome in the Phase III LEAP-010 (NCT04199104) study combining lenvatinib with pembrolizumab, other IO-TKI combinations show promise, such as the ongoing Phase III trial of pembrolizumab with zanzalintinib. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.